Novartis AG stock analysis
Novartis AG (0QLR) Share Price & Analysis
0QLR Stock Chart & Stats
- Day’s Range
- CHF 132.52 - CHF 134.75
- 52-Week Range
- CHF 99.45 - CHF 135.98
- Previous Close
- CHF 134.58
- Volume
- N/A
- Average Volume (3M)
- 684.68K
- Market Cap
- CHF 246.17B
- Enterprise Value
- CHF 261.65B
- Total Cash (Recent Filing)
- CHF 9.02B
- Total Debt (Recent Filing)
- CHF 48.53B
- Price to Earnings (P/E)
- 30.7
- Beta
- 1.03
- Next Earnings
- Feb 03, 2027 (Est.)
- EPS Estimate
- 1.84
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 2.79%
Bulls Say, Bears Say
Bulls Say
Priority-brand Growth
Rapid growth across multiple priority brands demonstrates meaningful commercial momentum and replacement power as older products face erosion. Broad adoption across oncology, immunology, neuroscience and cardiovascular care supports a diversified revenue base and strengthens medium-term growth durability.
Strong Profitability And Productivity
High operating profitability, gross-margin improvement and disciplined SG&A provide a strong earnings foundation. Productivity initiatives can help Novartis preserve margins while funding research and commercialization, supporting its commitment to achieve margins of 40% or more by 2029.
Pipeline And Growth Runway
The reaffirmed mid-single-digit growth outlook is supported by launches, label expansions and a broad pipeline spanning remibrutinib, pelabresib, Pluvicto and renal medicines. Multiple development programs and regulatory milestones create opportunities to extend growth beyond current brands.
Bears Say
Higher Leverage
The substantial increase in debt and debt-to-equity has reduced the balance-sheet cushion and financial flexibility. Higher leverage can constrain capital allocation and make the company more exposed to financing costs or operating weakness while it continues investing in its pipeline.
Patent And Biosimilar Erosion
Generic and biosimilar competition is already reducing contributions from established products and is expected to create further pressure, particularly for Xolair and European Entresto sales. This raises the execution burden on newer launches to replace lost revenue and profit.
Clinical And Pipeline Setbacks
Recent late-stage failures weaken the expected pipeline contribution and highlight development risk despite the breadth of Novartis's portfolio. The impairment also shows that setbacks can create material earnings volatility, while additional clinical work may delay potential launches.
Novartis AG News
0QLR FAQ
What was Novartis AG’s price range in the past 12 months?
What is Novartis AG’s market cap?
When is Novartis AG’s upcoming earnings report date?
How were Novartis AG’s earnings last quarter?
Is Novartis AG overvalued?
Does Novartis AG pay dividends?
What is Novartis AG’s EPS estimate?
How many shares outstanding does Novartis AG have?
What happened to Novartis AG’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Novartis AG?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
- Sector
- General
- Industry
- Drug Manufacturers - General
- CEO
- Vasant Narasimhan
- Employees
- 75,267
- Website
- www.novartis.com
- Address
- Lichtstrasse 35, Basel, BS, 4056, CH
Novartis AG (0QLR) Earnings & Revenues
0QLR Earnings Call
Earnings Call SentimentPositive
The call was broadly positive, with strong Q3 sales growth, core margin expansion, robust performance from priority brands, multiple pipeline and regulatory milestones, and an upgrade to full-year core operating income guidance. These positives were partly offset by major clinical setbacks, including the delgociptacine primary-endpoint miss and $1.9 billion impairment, the pelicarcen phase 3 failure, first-half generic erosion, expected Q4 margin pressure, and delays or uncertainty across several programs.
View all GB:0QLR earnings summaries0QLR Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 6 | 4 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 9 | 0 | 3 |
